Published March 12, 2026
| Version v1
Publication
Open
Soluble endoglin as a biomarker of cardiovascular and metabolic disorders related to endothelial dysfunction: a systematic review and meta-analysis
Authors/Creators
- 1. Faculty of Pharmacy in Hradec Kralove, Charles University
-
2.
Ghaem Hospital
-
3.
Mashhad University of Medical Sciences
-
4.
Chitkara University
Description
Abstract
Background and aims
Soluble endoglin (sENG) has been discussed as a biomarker of endothelial dysfunction, associated with cardiovascular and metabolic disorders. A critical evaluation of sENG as a diagnostic tool for atherosclerotic cardiovascular diseases (ASCVD), type 1 diabetes mellitus (DM1), type 2 diabetes mellitus (DM2), hypertensive disorders, and heart failure (HF) using a meta-analysis has never been performed.
Methods
PUBMED, SCOPUS, and Web of Science databases were searched up to August 1, 2025. Information on sENG concentrations in the group with one of the above-mentioned diagnoses and the control group was extracted and analyzed. Publication bias and quality assessment were performed using the Newcastle-Ottawa Scale (NOS) criteria.
Results
16 studies were evaluated. A total of 2113 subjects were included, comprising 1391 subjects in disease groups and 722 in the control group. sENG serum/plasma concentrations were significantly higher in disorders related to endothelial dysfunction than in controls, with a pooled mean difference of 0.92 ng/mL (95% CI: 0.50–1.34, p < 0.001). Additionally, sENG serum/plasma concentrations were significantly elevated in patients with DM1, 0.99 ng/mL (95% CI 0.45–1.54, p < 0.001), DM2, 1.98 ng/mL (95% CI 0.60–3.35, p = 0.005) and HF, 1.06 ng/mL (95% CI 0.06–2.06, p = 0.038), compared to controls.
Conclusions
This meta-analysis is the first to demonstrate that sENG serum/plasma concentrations are significantly higher in selected cardiovascular and metabolic disorders related to endothelial dysfunction. sENG might represent a novel biomarker reflecting endothelial damage only in patients with DM1, DM2, and heart failure.
Files
2026 Rathouska et al Soluble endoglin metaanalysis.pdf
Files
(5.9 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:95b2452fdb9674cceeddef3019705d86
|
5.9 MB | Preview Download |